Citation
Grossi, Cristina, et al. "Clioquinol Decreases Amyloid-beta Burden and Reduces Working Memory Impairment in a Transgenic Mouse Model of Alzheimer's Disease." Journal of Alzheimer's Disease : JAD, vol. 17, no. 2, 2009, pp. 423-40.
Grossi C, Francese S, Casini A, et al. Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 2009;17(2):423-40.
Grossi, C., Francese, S., Casini, A., Rosi, M. C., Luccarini, I., Fiorentini, A., Gabbiani, C., Messori, L., Moneti, G., & Casamenti, F. (2009). Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. Journal of Alzheimer's Disease : JAD, 17(2), 423-40. https://doi.org/10.3233/JAD-2009-1063
Grossi C, et al. Clioquinol Decreases Amyloid-beta Burden and Reduces Working Memory Impairment in a Transgenic Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2009;17(2):423-40. PubMed PMID: 19363260.
TY - JOUR
T1 - Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease.
AU - Grossi,Cristina,
AU - Francese,Simona,
AU - Casini,Angela,
AU - Rosi,Maria Cristina,
AU - Luccarini,Ilaria,
AU - Fiorentini,Anna,
AU - Gabbiani,Chiara,
AU - Messori,Luigi,
AU - Moneti,Gloriano,
AU - Casamenti,Fiorella,
PY - 2009/4/14/entrez
PY - 2009/4/14/pubmed
PY - 2009/12/17/medline
SP - 423
EP - 40
JF - Journal of Alzheimer's disease : JAD
JO - J Alzheimers Dis
VL - 17
IS - 2
N2 - Clioquinol (CQ) is a "metal protein attenuating compound" that crosses the blood-brain barrier and binds, with high affinity, copper(II) and zinc(II), two metal ions critically involved in amyloid-beta aggregation and toxicity. CQ was recently proposed for the treatment of Alzheimer's disease, but controversial data have been reported so far concerning its real therapeutic advantages. We describe here results of chronic CQ treatment in the TgCRND8 mouse model of Alzheimer's disease. Remarkably, based on classical behavioral tests, CQ treatment was found to reverse, to a large extent, the working memory impairments that are characteristic of this mouse model. Pairwise, a significant reduction of amyloid-beta plaque burden, both in the cortex and in the hippocampus, was detected as well as an attenuation of astrogliosis. MALDI Mass Spectrometry Imaging technique revealed a specific localization of CQ in the above mentioned brain areas. Modest but significant effects on the absolute and relative brain concentrations of the three most important biometals (i.e., copper, zinc, and iron) were highlighted following CQ treatment. The pharmacological and mechanistic implications of the above findings are thoroughly discussed.
SN - 1875-8908
UR - https://www.unboundmedicine.com/medline/citation/19363260/Clioquinol_decreases_amyloid_beta_burden_and_reduces_working_memory_impairment_in_a_transgenic_mouse_model_of_Alzheimer's_disease_
L2 - https://content.iospress.com/openurl?genre=article&issn=1387-2877&volume=17&issue=2&spage=423
DB - PRIME
DP - Unbound Medicine
ER -